Dengue Vaccine Globally
- A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people aged 9 to 45 years. The World Health Organization recommends that the vaccine only be given to persons with confirmed previous dengue virus infection.
- The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not been previously infected with a dengue virus may be at risk of developing severe dengue if they get dengue after being vaccinated.
Dengue Vaccine for U.S. Territories and Freely Associated States
- In May 2019, Dengvaxia was approved by the U.S. Food and Drug Administration (FDA) in the United States for use in children aged 9 to 16 years with laboratory-confirmed previous dengue virus infection and living in an area with endemic dengue.
- In June 2021, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended use of Dengvaxia to prevent dengue in children aged 9 to 16 years, with laboratory-confirmed previous dengue virus infection and living in areas where dengue is endemic.
- Dengvaxia will be available in 2022 for use in children and adolescents 9–16 years old who have laboratory-confirmed previous dengue virus infection and are living in an area where dengue is endemic (occurs frequently or continuously). Dengue-endemic areas include the U.S. territories of American Samoa, Puerto Rico, and the U.S. Virgin Islands, and freely associated states, including the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.
- Dengvaxia is not approved for use in U.S. travelers who are visiting but not living in an area where dengue is endemic.